Last reviewed · How we verify
Anti-IL12/23 or anti-IL23 - Risankizumab
Risankizumab is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway to reduce inflammatory immune responses.
Risankizumab is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway to reduce inflammatory immune responses. Used for Moderate to severe plaque psoriasis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | Anti-IL12/23 or anti-IL23 - Risankizumab |
|---|---|
| Sponsor | University of Calgary |
| Drug class | IL-23 inhibitor monoclonal antibody |
| Target | IL-23 (p19 subunit) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Risankizumab binds to the p19 subunit of IL-23, a key cytokine involved in driving Th17 cell differentiation and inflammatory responses. By specifically inhibiting IL-23 (rather than the broader IL-12/23 pathway), it reduces pathogenic inflammation while preserving some immune function. This selective mechanism has shown efficacy in inflammatory skin and bowel conditions driven by IL-23-mediated immunity.
Approved indications
- Moderate to severe plaque psoriasis
- Crohn's disease
- Ulcerative colitis
Common side effects
- Upper respiratory tract infection
- Headache
- Injection site reactions
- Nasopharyngitis
Key clinical trials
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease (PHASE3)
- Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors
- PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: